Combined chemotherapy and immunotherapy shows promise for advanced prostate cancers

April 29, 2015
Micrograph showing prostatic acinar adenocarcinoma (the most common form of prostate cancer) Credit: Wikipedia

Chemotherapy can be very effective against small prostate tumors. Larger prostate tumors, however, accumulate cells that suppress the body's immune response, allowing the cancer to grow despite treatment. Researchers at the University of California, San Diego School of Medicine now find that blocking or removing these immune-suppressing cells allows a special type of chemotherapy—and the immune cells it activates—to destroy prostate tumors. This novel combination therapy, termed chemoimmunotherapy, achieved near complete remission in mouse models of advanced prostate cancer.

The study is published April 29 in Nature.

Advanced or does not typically respond to chemotherapy. Prostate cancers also fail to respond to a promising new type of immunotherapy drugs, called checkpoint inhibitors, which disable cancer ' cloaking mechanism so that a person's own immune system can better fight the tumor. This specific resistance is likely due in part to immunosuppressive B cells, which are more common in larger in mice, as well as in advanced and metastatic prostate cancer in humans. As the name suggests, these cells keep the immune system at bay, rendering most therapies ineffective and allowing malignant tumors to grow unchecked.

In this study, researchers worked with three different mouse models of advanced prostate cancer. All three models were resistant to low doses of the chemotherapy drug oxaliplatin, which has the unique ability to activate cancer-killing . But when the researchers blocked the development or function of immunosuppressive B cells or removed them entirely before treating the mice with low-dose oxaliplatin, the prostate tumors were almost completely destroyed by the mice's own immune cells. The team got similar results when low-dose oxaliplatin was combined with a checkpoint inhibitor.

"The presence of such B cells in human prostate cancer calls for clinical testing of this novel therapeutic approach," said Shabnam Shalapour, PhD, postdoctoral researcher and first author of the study.

Prostate cancer is the second leading cause of cancer-related death in American men. About one in seven men will be diagnosed with prostate cancer during their lifetimes.

"In addition to prostate cancer, similar immunosuppressive B cells can be detected in other human cancers," said senior author Michael Karin, PhD, Distinguished Professor of Pharmacology and Pathology at UC San Diego. "This indicates that B cell-mediated immunosuppression might be the reason several other cancers are also unresponsive to checkpoint inhibitors, raising the hope that chemoimmunotherapy will have broader applications for many cancer types."

Explore further: Researchers find protein that may signal more aggressive prostate cancers

More information: Immunosuppressive plasma cells impede T-cell-dependent immunogenic chemotherapy, Nature, DOI: 10.1038/nature14395

Related Stories

Study identifies 'lethal' subtype of prostate cancer

March 16, 2015

A University of Colorado Cancer Center study published in the journal Cancer Research defines a new, distinct subtype of "lethal" prostate cancer marked by the loss of two genes, MAP3K7 and CHD1. Overall about 10 percent ...

New target for prostate cancer treatment discovered

February 20, 2015

Keck Medicine of the University of Southern California (USC) scientists have found a promising new therapeutic target for prostate cancer. The findings offer evidence that a newly discovered member of a family of cell surface ...

Healthy-looking prostate cells mask cancer-causing mutations

March 2, 2015

Prostate cells that look normal under the microscope may be hiding genetic mutations that could develop into cancer, prompting new ways to improve treatment for the disease, according to research published in Nature Genetics ...

HIV drug blocks bone metastases in prostate cancer

December 1, 2014

Although prostate cancer can be successfully treated in many men, when the disease metastasizes to the bone, it is eventually lethal. In a study published online December 1st in the journal Cancer Research, researchers show ...

Recommended for you

Researchers gain insight into breast cancer drug resistance

March 24, 2017

Breast cancer's ability to develop resistance to treatment has frustrated researchers and physicians and has thwarted even the latest and greatest targeted therapies. For example, after researchers identified a disease pathway ...

Three-pronged approach is key to precision medicine

March 23, 2017

Combining genetic information from a patient's tumor cells with three-dimensional cell cultures grown from these tumors and rapidly screening approved drugs can identify the best treatment approaches in patients for whom ...

Is there a link between telomere length and cancer?

March 23, 2017

Telomeres are regions of repetitive DNA at the end of human chromosomes, which protect the end of the chromosome from damage. Whilst shorter telomeres are hypothesized biological markers of older age and have been linked ...

How the nervous system controls tumor growth

March 22, 2017

(Medical Xpress)—From the time it first comes online during development the nervous system begins to exact precise control over many biologic functions. In some cases, too much control. When it does, a little nerve-squelching ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.